Compare BAFN & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | RGNT |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | Israel |
| Employees | N/A | 8 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 24.6M |
| IPO Year | 2021 | N/A |
| Metric | BAFN | RGNT |
|---|---|---|
| Price | $5.78 | $2.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.9K | ★ 677.4K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $1.23 |
| 52 Week High | $15.28 | $15.50 |
| Indicator | BAFN | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 39.53 |
| Support Level | $4.80 | $1.82 |
| Resistance Level | $5.90 | $3.35 |
| Average True Range (ATR) | 0.35 | 0.47 |
| MACD | 0.09 | -0.26 |
| Stochastic Oscillator | 81.82 | 0.19 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.